Actively Recruiting
Phase 1 Study of MR-Guided Focused Ultrasound Bilateral Capsulotomy for Treating Treatment-Resistant Bipolar Depression
Led by Sunnybrook Health Sciences Centre · Updated on 2025-08-06
10
Participants Needed
1
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and initial effectiveness of MR-guided focused ultrasound MRgFUS bilateral capsulotomy for patients with treatment-resistant bipolar depression TRBD. This is a prospective, single-arm, nonrandomized phase I study involving 10 participants. The study aims to assess symptom changes, adverse events, and quality of life after the procedure targeting the anterior limb of the internal capsule in the brain. Participants will undergo MRgFUS capsulotomy using the ExAblate Neuro 4000 device, which performs noninvasive thermal ablation under real-time MRI guidance. All participants receive the same treatment and will be followed for 24 months after the procedure to monitor clinical outcomes. The study includes a 2-month pre-treatment period and a total participation duration of approximately 26 months. During the study, participants will complete various clinical rating scales to measure depression, anxiety, mania, obsessive-compulsive symptoms, suicidal ideation, and quality of life. These assessments occur before treatment and at multiple follow-up points up to 24 months post-treatment. Safety monitoring is focused on adverse events from the treatment day through the follow-up period. The full study duration is about 3 years, with primary results expected within 2 to 3 years.
CONDITIONS
Brief Title
Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression
Research Team
N
Nir Lipsman, MD, PhD, FRCSC
A
Anusha Baskaran, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here